Nurse Practitioner, Family · Los Angeles, CA
NPI
1205484771
Since 2019
Specialty
Nurse Practitioner, Family
Code 363LF0000X
Group practices
1
Medicare group memberships
Hospitals
2
Hospital affiliations
200 UCLA Medical Plz Ste 120
Los Angeles, CA, 90095
Phone (310) 206-6909
Groups this clinician bills Medicare through
Medicare paid, 2024
$25K
378 services
Medicare patients, 2024
85
Average age 70
Drug cost, 2024
$5.7M
1,213 prescriptions
Company payments, 2025
$2,301
From 17 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Rachel L Schulz was code 99214 (office e&m - established), 320 times for 76 patients. In total Rachel L Schulz billed 378 services in 5 codes, and Medicare paid $25K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2023-11-20.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 99214 Office E&M - Established | Facility | 320 | 76 | $70.22 | $22K |
| 99213 Office E&M - Established | Facility | 37 | 18 | $35.56 | $1,316 |
By year: 2023 $2,524 for 54 services; 2024 $25K for 378 services.
Medicare prescription drug claims, 2024
In 2024, the drug Rachel L Schulz prescribed most often to Medicare patients was Acyclovir, with 97 prescriptions and refills. In total Rachel L Schulz wrote 1,213 Medicare prescriptions that cost $5.7M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Acyclovir Generic | 97 | 168 | 42 | $4,022 |
| Jakafi Ruxolitinib Phosphate | 70 | 70 | 16 | $975K |
| Rezurock Belumosudil Mesylate | 44 | 45 | Under 11 | $1.4M |
| Venclexta Venetoclax | 43 | 43 | 12 | $186K |
| Pantoprazole Sodium Generic | 42 | 104 | 20 | $314 |
| Lenalidomide Generic | 40 | 40 | Under 11 | $488K |
| Sulfamethoxazole-Trimethoprim Sulfamethoxazole/Trimethoprim | 39 | 69 | 18 | $367 |
| Gabapentin Generic | 33 | 37 | 11 | $847 |
| Leucovorin Calcium Generic | 32 | 57 | Under 11 | $594 |
| Pomalyst Pomalidomide | 32 | 32 | Under 11 | $681K |
| Levofloxacin Generic | 27 | 27 | 15 | $284 |
| Posaconazole Generic | 27 | 27 | Under 11 | $46K |
| Cresemba Isavuconazonium Sulfate | 27 | 31 | Under 11 | $175K |
| Revlimid Lenalidomide | 23 | 23 | Under 11 | $393K |
| Dexamethasone Generic | 22 | 34 | Under 11 | $505 |
Brand drugs: - claims; generic drugs: 770 claims; opioid claims: 31.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Rachel L Schulz $2,301 ($2,301 in general payments such as food, travel and fees) from 17 companies. The largest payer was Janssen Biotech, Inc. with $628.
| Company | Payments | Amount |
|---|---|---|
| Janssen Biotech, Inc. JNJ | 14 | $628 |
| Incyte Corporation INCY | 4 | $415 |
| Daiichi Sankyo Inc. 4568.T | 6 | $266 |
| Syndax Pharmaceuticals, Inc. SNDX | 2 | $174 |
| Pfizer Inc. PFE | 1 | $125 |
| Stryker Corporation SYK | 4 | $115 |
| Abbvie Inc. ABBV | 3 | $93.01 |
| Alexion Pharmaceuticals, Inc. AZN | 1 | $89.99 |
| Celgene Corporation BMY | 3 | $87.27 |
| BeOne Medicines USA, Inc. ONC | 3 | $76.3 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.